Conference Proceedings
Abstract P6-18-03: Biomarker analysis of CDK 4/6 and endocrine pathways in hormone-receptor positive (HR ) advanced breast cancer (ABC) bone only disease patients: A joint analysis of PALOMA-2 and PALOMA-3 studies
RS Finn, NC Turner, Y Liu, HS Rugo, S Loibl, V Diéras, DJ Slamon, F André, K Gelmon, A DeMichele, S Loi, Z Zhang, C Giorgetti, E Gauthier, C Huang Bartlett, M Cristofanilli
Cancer Research | American Association for Cancer Research (AACR) | Published : 2019
Abstract
Abstract Background: Palbociclib (PAL) in combination with endocrine therapy (ET) is a preferred treatment option for untreated and previously treated patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2 (HER2)–negative ABC. Patients with bone only disease could derive prolong disease control with single agent ET. Further understanding the predictive markers for sensitivity to ET alone and P+ET in both endocrine sensitive and resistant settings could help guide clinical treatment sequencing decision. We performed biomarker (BM) analysis of baseline tumor tissues in both PALOMA-2 (P2) and PALOMA-3 (P3) in bone only (BO) vs non-bone (NBO) only ..
View full abstract